ReviewBeilstein journal of organic chemistry2016
Antibiotics from predatory bacteria.
Review in Beilstein journal of organic chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed.
- Article
- Heterologous biosynthesis of myxobacterial lanthipeptides melittapeptins.Applied microbiology and biotechnology · 2024Article
- The EpiphyteBiomolecules · 2024Article
- Comprehensive Insights into Potential Metabolic Functions of Myxococcota in Activated Sludge Systems.Microbes and environments · 2024Article
- Interactions of DifferentInternational journal of molecular sciences · 2023Article
- Bivariate One Strain Many Compounds Designs Expand the Secondary Metabolite Production Space inMicroorganisms · 2023Article
- Two reasons to kill: predation and kin discrimination in myxobacteria.Microbiology (Reading, England) · 2023Review
- Phylogenetic Revisit to a Review on Predatory Bacteria.Microorganisms · 2023Review
- Aurachins, Bacterial Antibiotics Interfering with Electron Transport Processes.Antibiotics (Basel, Switzerland) · 2023Review
- Article
- Membrane Organization Strategies in Vesicular Antibiotic Delivery.The Journal of membrane biology · 2022Review
- Strategies to access biosynthetic novelty in bacterial genomes for drug discovery.Nature reviews. Drug discovery · 2022Review
- Three Rings to Rule Them All: How Versatile Flavoenzymes Orchestrate the Structural Diversification of Natural Products.Biochemistry · 2022Article
- The potential of facultative predatoryFrontiers in microbiology · 2022Review
- Concepts and conjectures concerning predatory performance of myxobacteria.Frontiers in microbiology · 2022Review
- Development versus predation: Transcriptomic changes during the lifecycle ofFrontiers in microbiology · 2022Article
- Venatorbacter cucullus gen. nov sp. nov a novel bacterial predator.Scientific reports · 2021Article
- Myxobacteria as a Source of New Bioactive Compounds: A Perspective Study.Pharmaceutics · 2021Review
- Article
- Identification of a solo acylhomoserine lactone synthase from the myxobacterium Archangium gephyra.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacteria, which prey on other microorganisms, are commonly found in the environment. While some of these organisms act as solitary hunters, others band together in large consortia before they attack their prey. Anecdotal reports suggest that bacteria practicing such a wolfpack strategy utilize antibiotics as predatory weapons. Consistent with this hypothesis, genome sequencing revealed that these micropredators possess impressive capacities for natural product biosynthesis. Here, we will present the results from recent chemical investigations of this bacterial group, compare the biosynthetic potential with that of non-predatory bacteria and discuss the link between predation and secondary metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.